What does this research mean for the field?

Integrating the tubular biomarker uDKK3 with albuminuria screening provides a more comprehensive approach to detecting and predicting progressive chronic kidney disease, particularly in non-albuminuric patients. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate urinary albumin and uDKK3 as biomarkers for early detection of CKD.

August 7, 2026Nephrology Dialysis TransplantationOpen Access

CKD screening: urinary albumin or uDKK3 or both?

View Full Paper

Ask AI

Bookmark

The aim is to evaluate urinary albumin and uDKK3 as biomarkers for early detection of CKD.
Clinical studies assessed uDKK3 levels alongside albuminuria in CKD populations.
Participants included adults and children with chronic kidney diseases.
Analysis focused on the predictive capacity of uDKK3 for progressive kidney function decline.
Elevated uDKK3 significantly improved detection of progressive CKD after adjusting for risk markers.
In non-albuminuric populations, uDKK3 identified high-risk individuals for kidney function decline.
Findings indicate distinct pathways of kidney injury, highlighting the need for complementary biomarker use.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial compares urinary albumin and uDKK3 for early CKD detection, suggesting improved screening strategies.

Cite This Study

Neuhaus et al. (2026) studied this question.

synapsesocial.com/papers/6a758bae847ab6d26c01f196 https://doi.org/10.1093/ndt/gfag166

View Full Paper

Ask AI

Bookmark

CKD screening: urinary albumin or uDKK3 or both?

Key Points

Discussion

Implication

Cite This Study

CKD screening: urinary albumin or uDKK3 or both?

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider